Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceutica...

Data : 25/03/2019 @ 08:40
Fonte : GlobeNewswire Inc.
Ativo : Wabash National Corp. (WNC)
Cotação : 14.72  -0.41 (-2.71%) @ 00:59
Cotação Gráfico

Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceutica...

Wabash (NYSE:WNC)
Gráfico Histórico do Ativo

3 Meses : De Mar 2019 até Jun 2019

Click aqui para mais gráficos Wabash.

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Mastercard Incorporated (NYSE:MA), Halliburton Company (NYSE:HAL), Keysight Technologies Inc. (NYSE:KEYS), Eli Lilly and Company (NYSE:LLY), Wabash National Corporation (NYSE:WNC), and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

MA DOWNLOAD: http://Capital-Review.com/register/?so=MA HAL DOWNLOAD: http://Capital-Review.com/register/?so=HAL KEYS DOWNLOAD: http://Capital-Review.com/register/?so=KEYS LLY DOWNLOAD: http://Capital-Review.com/register/?so=LLY WNC DOWNLOAD: http://Capital-Review.com/register/?so=WNC REGN DOWNLOAD: http://Capital-Review.com/register/?so=REGN

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Mastercard Incorporated (NYSE:MA), Halliburton Company (NYSE:HAL), Keysight Technologies Inc. (NYSE:KEYS), Eli Lilly and Company (NYSE:LLY), Wabash National Corporation (NYSE:WNC), and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 22nd, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

MASTERCARD INCORPORATED (MA) REPORT OVERVIEW

Mastercard's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Mastercard reported revenue of $3,807.00MM vs $3,312.00MM (up 14.95%) and analysts estimated basic earnings per share $0.88 vs $0.23 (up 282.61%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Mastercard reported revenue of $14,950.00MM vs $12,497.00MM (up 19.63%) and analysts estimated basic earnings per share $5.63 vs $3.67 (up 53.41%). Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.50. The estimated EPS forecast for the next fiscal year is $8.90 and is expected to report on January 30th, 2020.

To read the full Mastercard Incorporated (MA) report, download it here: http://Capital-Review.com/register/?so=MA

-----------------------------------------

HALLIBURTON COMPANY (HAL) REPORT OVERVIEW

Halliburton's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Halliburton reported revenue of $5,936.00MM vs $5,940.00MM (down 0.07%) and analysts estimated basic earnings per share $0.76 vs -$0.94. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Halliburton reported revenue of $23,995.00MM vs $20,620.00MM (up 16.37%) and analysts estimated basic earnings per share $1.89 vs -$0.53. Analysts expect earnings to be released on April 22nd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.41. The estimated EPS forecast for the next fiscal year is $2.06 and is expected to report on January 28th, 2020.

To read the full Halliburton Company (HAL) report, download it here: http://Capital-Review.com/register/?so=HAL

-----------------------------------------

KEYSIGHT TECHNOLOGIES INC. (KEYS) REPORT OVERVIEW

Keysight Technologies' Recent Financial Performance

For the three months ended January 31st, 2019 vs January 31st, 2018, Keysight Technologies reported revenue of $1,006.00MM vs $837.00MM (up 20.19%) and analysts estimated basic earnings per share $0.61 vs $0.50 (up 22.00%). For the twelve months ended October 31st, 2018 vs October 31st, 2017, Keysight Technologies reported revenue of $3,878.00MM vs $3,189.00MM (up 21.61%) and analysts estimated basic earnings per share $0.88 vs $0.57 (up 54.39%). Analysts expect earnings to be released on May 29th, 2019. The report will be for the fiscal period ending April 30th, 2019. Reported EPS for the same quarter last year was $0.77. The estimated EPS forecast for the next fiscal year is $4.07 and is expected to report on November 19th, 2019.

To read the full Keysight Technologies Inc. (KEYS) report, download it here: http://Capital-Review.com/register/?so=KEYS

-----------------------------------------

ELI LILLY AND COMPANY (LLY) REPORT OVERVIEW

Eli Lilly's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Eli Lilly reported revenue of $6,438.60MM vs $6,160.70MM (up 4.51%) and basic earnings per share $1.10 vs -$1.58. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Eli Lilly reported revenue of $24,555.70MM vs $22,871.30MM (up 7.36%) and analysts estimated basic earnings per share $3.14 vs -$0.19. Analysts expect earnings to be released on April 23rd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.34. The estimated EPS forecast for the next fiscal year is $6.46 and is expected to report on February 5th, 2020.

To read the full Eli Lilly and Company (LLY) report, download it here: http://Capital-Review.com/register/?so=LLY

-----------------------------------------

WABASH NATIONAL CORPORATION (WNC) REPORT OVERVIEW

Wabash National's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Wabash National reported revenue of $610.20MM vs $543.44MM (up 12.28%) and analysts estimated basic earnings per share $0.22 vs $0.84 (down 73.81%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Wabash National reported revenue of $2,267.28MM vs $1,767.16MM (up 28.30%) and analysts estimated basic earnings per share $1.22 vs $1.88 (down 35.11%). Analysts expect earnings to be released on May 7th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.28. The estimated EPS forecast for the next fiscal year is $1.43 and is expected to report on February 4th, 2020.

To read the full Wabash National Corporation (WNC) report, download it here: http://Capital-Review.com/register/?so=WNC

-----------------------------------------

REGENERON PHARMACEUTICALS, INC. (REGN) REPORT OVERVIEW

Regeneron Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Regeneron Pharmaceuticals reported revenue of $1,927.80MM vs $1,582.42MM (up 21.83%) and analysts estimated basic earnings per share $7.59 vs $1.61 (up 371.43%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Regeneron Pharmaceuticals reported revenue of $6,710.80MM vs $5,872.20MM (up 14.28%) and analysts estimated basic earnings per share $22.65 vs $11.27 (up 100.98%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $3.98. The estimated EPS forecast for the next fiscal year is $20.78 and is expected to report on February 5th, 2020.

To read the full Regeneron Pharmaceuticals, Inc. (REGN) report, download it here: http://Capital-Review.com/register/?so=REGN

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Nicole Garrens, Media Department Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Seu Histórico Recente
BOV
VALE5
Vale PNA
BOV
IBOV
iBovespa
BOV
PETR4
Petrobras
BOV
IGBR3
IGB SA
FX
USDBRL
Dólar EUA ..
Ações já vistas aparecerão nesta caixa, facilitando a volta para cotações pesquisadas anteriormente.

Registre-se agora para criar sua própria lista de ações customizada.

Cotações da NYSE e AMEX têm defasagem de no mínimo 20 minutos.
Quaisquer outras cotações têm defasagem de no mínimo 15 minutos quando não especificado.
Em caso de dúvidas por favor entre em contato com o suporte: suporte@advfn.com.br ou (11) 4191 5205.
P: V:br D:20190616 15:45:21